Us Bancorp \De\ Cullinan Oncology, Inc. Transaction History

Us Bancorp \De\

$78.3 Billion
Q2 2025

A detailed history of Us Bancorp \De\ transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 295 shares of CGEM stock, worth $2,457. This represents 0.0% of its overall portfolio holdings.

Number of Shares

295

Previous 1,557 81.05%

Holding current value

$2,457

Previous $11,000 81.82%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 23, 2025	SELL	$7.13 - $9.08 $8,998 - $11,458	-1,262 Reduced 81.05%	295 $2,000
Q1 2025 May 08, 2025	BUY	$7.57 - $12.68 $10,174 - $17,041	1,344 Added 630.99%	1,557 $11,000
Q4 2024 Feb 05, 2025	BUY	$10.77 - $17.6 $1,033 - $1,689	96 Added 82.05%	213 $2,000
Q3 2024 Oct 28, 2024	BUY	$16.03 - $20.86 $192 - $250	12 Added 11.43%	117 $1,000
Q2 2024 Aug 06, 2024	SELL	$15.63 - $29.35 $5,048 - $9,480	-323 Reduced 75.47%	105 $1,000
Q1 2024 May 07, 2024	SELL	$10.17 - $19.02 $772 - $1,445	-76 Reduced 15.08%	428 $7,000
Q4 2023 Feb 09, 2024	BUY	$7.89 - $10.23 $3,976 - $5,155	504 New	504 $5,000
Q1 2023 May 09, 2023	BUY	$10.2 - $11.91 $5,273 - $6,157	517 Added 91.18%	1,084 $11,000
Q4 2022 Feb 13, 2023	SELL	$9.72 - $13.62 $1,069 - $1,498	-110 Reduced 16.25%	567 $5,000
Q3 2022 Oct 27, 2022	BUY	$11.82 - $15.42 $2,198 - $2,868	186 Added 37.88%	677 $9,000
Q2 2022 Aug 01, 2022	SELL	$7.31 - $13.55 $9,261 - $17,167	-1,267 Reduced 72.07%	491 $6,000
Q1 2022 May 11, 2022	BUY	$10.47 - $16.75 $3,224 - $5,159	308 Added 21.24%	1,758 $18,000
Q4 2021 Feb 11, 2022	BUY	$15.36 - $25.0 $22,118 - $36,000	1,440 Added 14400.0%	1,450 $22,000
Q3 2021 Nov 10, 2021	BUY	$22.56 - $29.68 $225 - $296	10 New	10 $0

Others Institutions Holding CGEM

# of Institutions

155

Shares Held

68.5M

Call Options Held

15.6K

Put Options Held

17.9K

View Full List

About Cullinan Oncology, Inc.

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $380M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

More about CGEM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account